Szlosek Thomas A

Director Szlosek buys 20,308 shares of RXO at $12.37; stock down 60.0% from 52-week high, yet company grew revenue 15.9% YoY.

Director Thomas A Szlosek purchased 20,308 shares of RXO at $12.37, a substantial $251.2K commitment. The purchase occurs after the stock has declined 60.0% from its 52-week high and is down 24.4% over the preceding 30 days, suggesting a willingness to deploy capital during a meaningful drawdown. At his same ticker (RXO), prior buys have shown mixed near-term results (30-day range from -7.8% to +11.2%), though his cross-ticker track record shows stronger outcomes with a 75.00% 90-day win rate. Notably, the company remains unprofitable (net income of $-14.0M in the latest quarter) despite posting solid annual revenue growth of 15.9%, creating a tension between growth trajectory and current earnings power that warrants attention to RXO's path to profitability.

Director Szlosek buys 7,500 RXO shares at $16.65; prior buy 5 days earlier signals continued accumulation in unprofitable company.

Thomas A Szlosek, a director, purchased 7,500 shares at $16.65 on 2025-05-14, increasing his holdings by 86.2% from 8,700 to 16,200 shares. This transaction is notable because it occurred just five days after another open-market purchase at the same ticker (2025-05-09), suggesting a deliberate pattern of accumulation. The company remains unprofitable with net income of $-31,000,000.00 and a market cap of $2,829,192,317.50, yet shows annual revenue growth of +15.9%, indicating operational expansion against current losses. Szlosek's prior trade at RXO in 2023 produced a +28.6% 90-day return, and his cross-ticker track record shows a 100.00% win rate on buys at the 90-day mark with avg 90d return +23.7%, establishing a history of well-timed acquisitions.

RXO Director Szlosek buys 8,700 shares at $14.41; stock now at $16.62, +21.5% in 30 days

Director Thomas A Szlosek purchased 8,700 shares at $14.41 on 2025-05-09, establishing an initial position in RXO from zero prior holdings. The stock has rallied 21.5% over the past 30 days and currently trades at $16.62, 47.9% below its 52-week high of $31.90. Szlosek's prior transaction at RXO (buy on 2023-09-15) generated a 90-day return of +28.6%, indicating a pattern of buying at levels that preceded subsequent appreciation. However, RXO remains unprofitable with a net income of $-31.0M on revenue of $1.4B, despite annual revenue growth of 15.9%, warranting close attention to whether fundamental trajectory supports the recent price momentum.